Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Key Points
Key points are not available for this paper at this time.
Abstract
Inclusion Criteria, Exclusion Criteria, Dose Limiting Toxicity Criteria for First Cycle
Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors | Synapse